Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

/PRNewswire/ -- Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient...

Related Keywords

Mark Egerton ,Lynn Kirkpatrick ,Ensysce Biosciences ,Prnewswire Ensysce Biosciences Inc ,Quotient Sciences ,Translational Pharmaceutics ,Ensysce Biosciences Inc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,Joint Ventures ,